Pharmafile Logo
Pharmafocus logo
Advanced Search

blood cancer

Showing 15 posts of 28 posts found.

Regeneron plans to share advancements from blood cancer pipeline

November 6, 2023
Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology

Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …

News

Antion launch new technology for cancer and tumour treatments

March 18, 2021
Cancer, action, blood cancer, myeloma

Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases …

News

ONK and Anthony Nolan combine forces to work on blood cancer therapies

February 22, 2021
Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment

ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …

News
cancer-cells-541954_960_720

Researchers find Achilles’ heel protein in leukaemia

April 26, 2019
Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia

An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
shutterstock_159488225

Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds

December 13, 2017
Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma

The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …

News
roche_dark_0

FDA expands Roche drug indication to approve first-ever treatment for rare blood cancer

November 7, 2017
Manufacturing and Production, Sales and Marketing Cancer, Erdheim-Chester Disease, FDA, Roche, blood cancer, pharma

The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already …

News
blood-75301_640

Existing arthritis drug could save thousands in blood cancer treatment

August 3, 2017
Research and Development University of Sheffield, arthritis, biotech, blood cancer, drugs, life sciences, medicine, pharma, pharmaceutical

Findings by researchers at the University of Sheffield have indicated that thousands of pounds could be saved in blood cancer …

News

Bayer celebrates FDA priority review for investigational blood cancer drug

May 17, 2017
Research and Development, Sales and Marketing Bayer, FDA, blood cancer

Bayer has announced that its investigational blood cancer treatment copanlisib has been awarded priority review designation from the FDA, meaning …

News

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …

News
amgen_hq

Amgen says its blood cancer drug gets European backing for extended indication

July 4, 2016
Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial

Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …

News
cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …

News
celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016
Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …

News
janssen_latest_logo_on_sign_closer

Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study

June 14, 2016
Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica

Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …

News
gilead-sciences

EMA starts review of Gilead Sciences’ Zydelig following safety concerns

March 14, 2016
Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig

Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024